Abstract
The clinical outcome of patients with the various manifestations of collagen vascular disease (CVD) has significantly improved over the past two decades with the increased use of diuretics, cytotoxic agents, dialysis, transplantation, and the judicious use of corticosteroids and other antiinflammatory agents directed at altering or delaying end-organ damage by the underlying immunopathologic process. 1–4 A more rigorous definition of the various CVD clinical syndromes and a greater sophistication in the serologic, radiologic, and pathologic diagnostic methods have meant that patients with these diseases are now coming to clinical attention earlier in the course of their illness. Consequently, the physician is now encountering a greater number of clinical problems over a longer time span for each individual patient, rather than just the well-known complications of their end-stage disease. Despite the beneficial aspects of the newer therapeutic interventions to improve the clinical outcome of patients with CVD, the incidence of infection as a cause of both morbidity and mortality in these patients has not changed significantly over the past 30 years. 1–19 A number of factors discussed in this chapter most likely contribute to the persistence of infectious complications in these patients. These include underlying host-defense abnormalities not significantly altered by therapeutic interventions, prolonged therapy with corticosteroids, and alkylating agents that further suppress an already abnormal immune response, and an increased frequency of hospitalizations with more aggressive medical and surgical interventions, thereby increasing the risk of nosocomial infectious complications.
Chapter PDF
Similar content being viewed by others
Keywords
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis Patient
- Septic Arthritis
- Total Joint Arthroplasty
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Carpenter RC, Sturgill BC: The course of systemic lupus erythematosus. J Chronic Dis 19: 117–131, 1966.
Dubois EL, Tuffanelli DL: Clinical manifestations of systemic lupus erythematosus: Computer analysis of the 520 cases. JAMA 190: 112–119, 1964.
Perez HD, Goldstein IM: Infection and host defenses in systemic lupus erythematosus. In Franklin EC (ed): Clinical Immunology Update Elsevier, New York, 1979, pp. 133159.
Steinberg AD: Management of systemic lupus erythematosus. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 1098–1115.
Coplon NS, Diskin CJ, Petersen SJ, et al: The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 308: 186–190, 1983.
Cohen J, Pinching Ai: Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1–15, 1982.
Platt JL, Burke, BA, Fish Ai, et al: Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 2 (suppl 1): 212–222, 1982.
Rosner S, Ginzler EM, Diamond HS, et al: A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 6: 612–617, 1982.
Kiernan M, Bresnihan B: Clinical features and outcome of infection in systemic lupus erythematosus. Ir J Med Sci 152: 382–386, 1983.
Wallace DJ, Podell TE, Weiner JM, et al: Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72: 209–220, 1982.
Hashimoto H, Shiokawa Y: Changing pattern of clinical features and prognosis in systemic lupus erythematosus. Scand J Rheumatol 7: 219–224, 1978.
Ginzler E, Diamond H, Kaplan D, et al: Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21: 37–44, 1978.
Fish Ai, Blau EB, Westerberg NG, et al: Systemic lupus erythematosus within the first two decades of life. Am J Med 62: 99–117, 1977.
Urowitz MB, Bookman AA, Koehler BE, et al: The biomodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221–225, 1976.
Staples PG, Gerding DN, Decker JL, et al: Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 17: 1–10, 1974.
Vandenbroucke JP, Hazevoet HM, Cats A: Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup. J Rheumatol 11: 158–161, 1984.
Hollingsworth JW, Saykaly RI: Systemic complications of rheumatoid arthritis. Med Clin North Am 61: 217–228, 1977.
Prior P, Symmons DP, Scott DL, et al: Cause of death in rheumatoid arthritis. Br J Rheumatol 23: 92–99, 1984.
Lee P, Urowitz MB, Bookman AAM, et al: Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 181: 1–32, 1977.
Rothfield N: Clinical features of systemic lupus erythematosus. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 1070–1907.
Harris ED Jr: Rheumatoid arthritis: The clinical spectrum. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 915–950.
Myers AR: Septic arthritis caused by bacteria: In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology WB Saunders, Philadelphia, 1985, pp. 15071527.
Schnitzer TJ: Viral arthritis. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 1540–1556.
Benson CH, Harisdangkul V: Disseminated gonococcal infection in systemic lupus erythematosus. (Letter.) J Rheumatol 10: 668–669, 1983.
Churchill MA, Geraci JE, Hunder GG: Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 87: 754–757, 1977.
Ellis SG, Verity MA: Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologie findings in 57 cases, 1955–1977. Sem Arch Rheum 8: 21 2221, 1979.
Johnson R, Richardson E: The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 47: 1399–1402, 1968.
Schur PH: Systemic lupus erythematosus. In Wyngaarden JB, Smith LH Jr (eds): Cecil Textbook of Medicine. WB Saunders, Philadelphia, 1982, pp. 1852–1857.
Mitchell WS, Brooks PM, Stevenson RD, et al: Septic arthritis in patients with rheumatoid disease: A still underdiagnosed complication. J Rheumatol 3: 124–133, 1976.
Huskisson EC, Hart FD: Severe, unusual, and recurrent infections in rheumatoid arthritis. Ann Rheum Dis 31: 118121, 1972.
Walker WC: Pulmonary infections and rheumatoid arthritis. Q J Med 36: 239–251, 1967.
Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol Lab Med 32: 569631, 1941.
Ropes MW: Observations on the natural course of disseminated lupus erythematosus. Medicine (Baltimore) 43: 387391, 1964.
Dubois EL, Wierzchowiecki M, Cox MB, et al: Duration and death in systemic lupus erythematosus: An analysis of 249 cases. JAMA 227: 1399–1402, 1974.
Harvey AM, Shulman LE, Tumulty PA, et al: Systemic lupus erythematosus: Review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33: 291–437, 1954.
Estes D, Christian CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 50: 85–95, 1971.
Hashimoto H, Shiokawa Y: Changing pattern of clinical features and prognosis in systemic lupus erythematosus. Scand J Rheum 7: 219–224, 1978.
Allebeck P: Increased mortality in rheumatoid arthritis. Scand J Rheum 11: 81–86, 1982.
Koota K, Isomaki H, Mutra 0: Death rate and causes of death in RA patients during a period of five years. Scand J Rheum 6: 241–244, 1977.
Mutra 0, Koota K, Isomaki H: Causes of death in autopsied RA patients. Scand J Rheum 5: 239–240, 1976.
Cosh JA: Survival and death in rheumatoid arthritis. J Rheum 11: 117–118, 1984.
Zvaifler NJ, Woods VL Jr: Etiology and pathogenesis of systemic lupus erythematosus. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 1042–1070.
Bennett JC: The etiology of rheumatoid arthritis. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology WB Saunders, Philadelphia, 1985, pp. 879886.
Harris ED Jr: Pathogenesis of rheumatoid arthritis. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology WB Saunders, Philadelphia, 1985, pp. 886915.
Johnston RB, Stroud RM: Complement and host defense against infection. J Pediatr 90: 169–179, 1977.
Muller-Eberhard HJ: Complement. Annu Rev Biochem 44: 697–724, 1975.
Shur PH: Complement in lupus. Clin Rheum Dis 1:519–524, 1975.
Kaplan RA, Curd JG, DeHeer DH, et al: Metabolism of C4 and factor B in rheumatoid arthritis: relation to rheumatoid factor. Arthritis Rheum 23: 911–924, 1980.
Kohler PF, Ten Beusel R: Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol 4: 1091–1202, 1969.
Jasin HE, Ziff M: Immunoglobulin synthesis by peripheral blood cells in systemic lupus erythematosus. Arthritis Rheum 18: 219–228, 1975.
McLean RH, Michael AF: Properdin and C3 proactivator: Alternate pathway components in human glomerulonephritis. J Clin Invest 52: 634–644, 1973.
Schur PH, Sandson J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278: 533–535, 1968.
Ellis HA, Felix-Davies D: Serum complement, rheumatoid factor, and other serum proteins in rheumatoid disease and systemic lupus erythematosus. Ann Rheum Dis 18: 215–244, 1959.
Ross SC, Densen P: Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63: 243–273, 1984.
Jazin HE, Orozco JH, Ziff M: Serum heat-labile opsonins in systemic lupus erythematosus. J Clin Invest 53: 343–353, 1974.
Louie JS, Nies KM, Shoji KT, et al: Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 88: 790–792, 1978.
Williams GW, Steinberg AD, Reinertsen JL, et al: Influenza immunization in systemic lupus erythematosus. Ann Intern Med 88: 729–734, 1978.
Hess EV: Influenza immunization in systemic lupus erythematosus: Safe, effective? Ann Intern Med 88: 833–834, 1978.
Meiselas LE, Zingale SB, Lee SL, et al: Antibody production in rheumatic diseases: The effect of Brucella antigen. J Clin Invest 40: 1872–1881, 1961.
Baum J, Ziff M: Decreased 19S antibody response to bacterial antigens in systemic lupus erythematosus. J Clin Invest 48: 758–767, 1969.
Messner RP, DeHoratius RJ: Epidemiology of anti-lymphocyte antibodies in systemic lupus erythematosus. Arthritis Rheum 21: S167–169, 1978.
Bluestein HG: Autoantibodies to lymphocyte membrane antigens: Pathogenetic implications. Clin Rheum Dis 4: 643647, 1978.
Winfield JB, Cohen PL, Litvin DA: Antibodies to activated cells and their soluble products in systemic lupus erythematosus. Arthritis Rheum 25: 814–819, 1982.
Clark RA, Kimball HR, Decker JL: Neutrophil chemotaxis in systemic lupus erythematosus. Ann Rheum Dis 33: 167–172, 1974.
Goetz EJ: Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty’s syndrome and systemic lupus erythematosus. Ann Rheum Dis 35: 510–515, 1976.
Perez HD, Lipton M, Goldstein IM: A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 62: 29–38, 1978.
Perez HD, Andron RI, Goldstein IM: Infection in patients with systemic lupus erythematosus. Association with a serum inhibitor of complement-derived chemotactic activity. Arthritis Rheum 22: 1326–1333, 1979.
Brandt L, Hedberg H: Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scand J Haematol 6: 348–353, 1969.
Wenger ME, Bole GG: Nitroblue tetrazolium dye reduction by peripheral leukocytes from rheumatoid arthritis and systemic lupus erythematosus patients measured by a histochemical and spectrophotometric method. J Lab Clin Med 82: 513–521, 1973.
Kamovsky ML: The metabolism of leukocytes. Semin Hematol 5: 156–165, 1968.
McLeod R, Wing EJ, Remington JS: Lymphocytes and macrophages in cell-mediated immunity. In Mandell GL, Douglas RG, Bennett JE (eds): Principles and Practice of Infectious Diseases. Wiley, New York, 1985, pp. 72–93.
Hahn BH, Bagby MK, Osterland CK: Abnormalities of delayed hypersensitivity in systemic lupus erythematosus. Am J Med 55: 25–30, 1973.
Rosenthal CJ, Franklin DC: Depression of cellular-mediated immunity in systemic lupus erythematosus. Arthritis Rheum 18: 208–212, 1975.
Horowitz DA: Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum 15: 353–355, 1972.
Sakane T, Steinberg AD, Green I: Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 75: 3464–3467, 1978.
Smolen JS, Chused TM, Leiserson WM, et al: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med 72: 783–786, 1982.
Ginsberg WW, Finkelman FD, Lipsky PE: Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol 35: 76–80, 1979.
Sagawa A, Abdou NI: Suppressor-cell dysfunction in systemic lupus erythematosus: Cells involved and in vitro correction. J Clin Invest 62: 789–794, 1978.
Katz P, Zaytoun AM, Lee JH Jr, et al: Abnormal natural killer cell activity in systemic lupus erythematosus: An intrinsic defect in the lytic event. J Immunol 129: 1966–1970, 1982.
Hasler F, Bluestein HG, Zvaifler NJ, et al: Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation, J Exp Med 157: 173–179, 1983.
Trentham DE, Dynesius RA, Rocklin RE, et al: Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med 299: 327–331, 1978.
Dohlong JH, Forre 0, Kvien TK, et al: Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis. Ann Rheum Dis 41: 490–494, 1982.
Parillo JE, Fauci AS: Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 19: 179–191, 1979.
Axelrod L: Glucocorticoids. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. WB Saunders, Philadelphia, 1985, pp. 815–832.
Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Am Intern Med 84: 304–315, 1976.
Bovornkitti S, Kangsadal P, Sathirpat P, et al: Reversion and reconversion rate of tuberculin skin reactions in correlation with the use of prednisone. Dis Chest 38: 51–55, 1960.
Balow JE, Rosenthal AS: Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 137: 1031–1042, 1973.
DeSousa M, Fachet J: The cellular basis of the mechanism of action of cortisone acetate on contact sensitivity to oxazolone in the mouse, Clin Exp Immunol 10: 673–684, 1972.
Reinehart JJ, Sagone AL, Balcerzak SP: Effects of corticosteroid therapy on human monocyte function. N Engl J Med 292: 236–241, 1975.
Fauci AS, Dale DC: The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 53: 240–246, 1974.
Stavy L, Cohen IR, Feldman M: The effect of hydrocortisone on lymphocyte-mediated cytolysis. Cell Immunol 7: 302–312, 1973.
Bishop CR, Athens JW, Boggs DR, et al: Leukokinetic studies XIII: A non steady-state kinetic evaluation of the mechanisms of cortisone-induced granulocytosis, J Clin Invest 47: 249–261, 1968.
Butler WT, Rossen RD: Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methyl prednisolone. J Clin Invest 52: 2629–2640, 1973.
Atkinson JP, Frank MM: Effects of cortisone therapy on serum complement components. J Immunol 111: 1061–1066, 1973.
Robinson DR, Tashjian AH Jr, Levine L: Prostaglandin-stimulated bone resorption by rheumatoid synovia: A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 56: 1181–1189, 1975.
Samuelsson B: Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568–572, 1983.
Shand FL: The immunopharmacology of cyclophosphamide. Int J Pharmacol 1: 165–180, 1979.
Decker JL: Toxicity of immunosuppressive drugs in man. Arthritis Rheum 16: 89–101, 1973.
Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128: 2453–2457, 1982.
Hurd ER, Giuliano VJ: The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum 18: 67–75, 1975.
Askenase PW, Hayden BJ, Gershon RK: Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not effect antibody responses. J Exp Med 141: 697–703, 1975.
Yu DT, Clements PJ, Peter JB, et al: Lymphocyte characteristics in rheumatic patients and the effects of azathioprine therapy. Arthritis Rheum 17: 37–43, 1974.
Maibach HI, Epstein WL: Immunologic responses of healthy volunteers receiving azathioprine (Imuran). IntArch Allergy 27: 102–107, 1965.
Fournier C, Bach MA, Dardenne M, Bach JF: Selective action of azathioprine on T cells. Transplant Proc 5: 523527, 1973.
Gassman AE, vanFurth R: The effects of azathioprine on the kinetics of monocytes and macrophages during the normal steady state and an acute inflammatory reaction. Blood 46: 51–59, 1975.
Levy J, Barnett EV, MacDonald NS, et al: The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest 51: 2233–2238, 1972.
Schultz DR, Volanakis JE, Arnold PI, et al: Inactivation of C1 in rheumatoid synovial fluid, purified Cl and Cl esterase, by gold compounds. Clin Exp Immunol 17: 395–401, 1974.
Paltemaa S: The inhibition of lysosomal enzymes by gold salts in human synovial fluid cells. Acta Rheum Scand 14: 161–165, 1968.
Penneys NS, Ziboh V, Gottlieb NL, et al: Inhibition of prostaglandin synthesis and human epidermal enzymes by aurothiomalate in vitro: Possible actions of gold in pemphigus. J Invest Dermatol 63: 356–361, 1974.
Jessop JE, Vernon-Roberts B, Harris, J: Effects of gold salts and prednisolone on inflammatory cells. Ann Rheum Dis 32: 294–301, 1973.
Lies RB, Cardin C, Paulus HE: Inhibition by gold of human lymphocyte stimulation. Ann Rheum Dis 36: 216–220, 1977.
Cohen J, Pinching AJ, Rees AJ, et al: Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1–15, 1982.
Hashimoto H, Maekawa S, Nasu H, et al: Systemic vascular lesions and prognosis in systemic lupus erythematosus. Scand J Rheum 13: 45–55, 1984.
Baum J: Infection and rheumatoid arthritis. Arthritis Rheum 14: 135–137, 1971.
Poss R, Thornhill TS, Ewald FC, et al: Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop 182: 117–126, 1984.
Stahl NI, Klippel JH, Decker JL: Fever in systemic lupus erythematosus. Am J Med 67: 935–940, 1979.
Siekert RG, Clark EC: Neurologic signs and symptoms as early manifestations of SLE. Neurology (NY) 5: 84–88, 1955.
Feinglass EJ, Arnett FC, Dorsch CA, et al: Neuropsychiatric manifestations of SLE: diagnosis, clinical spectrum and relationship to other features of the disease. Medicine (Baltimore) 55: 323–339, 1976.
Reintz E, Hubbard D, Grayzel AI: Central nervous system systemic lupus erythematosus versus central nervous system infection: Low cerebral spinal fluid glucose and pleocytosis in a patient with a prolonged course. Arthritis Rheum 25: 583–588, 1982.
Gibson T, Myers AR: Nervous system involvement in SLE. Ann Rheum Dis 35: 398–406, 1976.
Andrianakos AA, Duffy J, Suzuki M, Sharp JT: Transverse myelopathy in SLE. Ann Intern Med 83: 616–624, 1975.
Collins JV, Tong D, Bucknall RG, et al: Cryptococcal meningitis as a complication of systemic lupus erythematosus treated with systemic corticosteroids. Postgrad Med J 48: 52–55, 1972.
Sieving RR, Kaufman CA, Watanakunakor C: Deep fungal infection in systemic lupus erythematosus: Three cases reported, literature reviewed. J Rheumatol 2: 61–72, 1975.
Bennett J, Dismukes W, Duma R, et al: A collaborative trial of flucytosine-amphotericin B and amphotericin B alone in cryptococcal meningitis. N Engl J Med 301: 126–130, 1979.
Diamond RD, Bennett JE: Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med 80: 176181, 1974.
Matthay RA, Schwarz MI, Petty TL, et al: Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 54: 397–409, 1974.
Haupt HM, Moore GW, Hutchins GM: The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 71: 791–798, 1981.
Matthay RA, Schwarz MI, Petty TL: Pleuro-pulmonary manifestations of connective tissue diseases. Clin Notes Respir Dis 16: 3–9, 1977.
Hunninghake GW, Fauci AS: Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 119: 47 1503, 1979.
Israel HL: The pulmonary manifestations of disseminated lupus erythematosus. Am J Med Sci 226: 387–392, 1953.
Webb WR, Gamsu G: Cavitary pulmonary nodules with systemic lupus erythematosus: Differential diagnosis. Am J Radiol 136: 27–31, 1981.
Eagen JW, Memoli VA, Roberts JL: Pulmonary hemorrhage in systemic lupus erythematosus. Medicine (Baltimore) 57: 545–560, 1978.
Feng PH Tan TH: Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 41:11–14,1982.
Millar JW, Horne NW: Tuberculosis in immunosuppressed patients. Lancet 1: 1176–1178, 1982.
Palmer DL, Harvey RL, Wheeler JK: Diagnostic and therapeutic considerations in Nocardia asteroides infection. Medicine (Baltimore) 53: 391–401, 1974.
Gorevic PD, Katler EI, Argus B: Pulmonary nocardiosis. Occurrence in men with systemic lupus erythematosus. Arch Intern Med 140: 361–364, 1980.
O’Neill PB: Gastrointestinal abnormalities in ‘the collagen diseases. Am J Dig Dis 6: 1069–1085, 1961.
Hoffman BI, Katz WA: The gastrointestinal manifestations of systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 9: 237–247, 1980.
Zizic TM, Classen JN, Stevens MB: Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 73: 525–531, 1982.
Pollack VE, Grove WJ, Kark RM, et al: Systemic lupus erythematosus simulating acute surgical condition of the abdomen. N Engl J Med 259: 258–266, 1958.
Reynolds J: Acute pancreatitis in systemic lupus erythematosus: Report of 20 cases and review of the literature. Medicine (Baltimore) 61: 25–32, 1982.
Lipsky PE, Hardin JA, Schour L, et al: Spontaneous peritonitis and systemic lupus erythematosus. JAMA 232: 929931, 1975.
Seinknecht CW, Urowitz MB, Pruzanski W, et al: Felty’s syndomre: Clinic and serologic analysis of 34 cases. Ann Rheum Dis 36: 500–507, 1977.
Ortbals DW, Man JJ: A comparative study of tuberculosis and other mycobacterial infections and their association with malignancy. Am Rev Respir Dis 117: 39–45, 1978.
DeMerieux PA, Keystone EC, Hutcheon M, et al: Polyarthritis due to Mycobacterium kansasii in a patient with rheumatoid arthritis. Ann Rheum Dis 39: 90–94, 1980.
Hoffman GS, Myers RL, Stark FR, et al: Septic arthritis associated with Mycobacterium avium: A case report and literature review. J Rheum 5: 199–209, 1978.
Quismorio FP, Dubois EL: Septic arthritis in systemic lupus erythematosus. J Rheum 2: 73–82, 1975.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer Science+Business Media New York
About this chapter
Cite this chapter
Payan, D.G. (1988). Evaluation and Management of Infections in Patients with Collagen Vascular Disease. In: Rubin, R.H., Young, L.S. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6645-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6645-8_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-6647-2
Online ISBN: 978-1-4615-6645-8
eBook Packages: Springer Book Archive